KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares Outstanding
Ratios

Biogen (BIIB) Shares Outstanding (2016 - 2025)

Biogen has reported Shares Outstanding over the past 14 years, most recently at $170.5 million for Q3 2025.

  • For Q3 2025, Shares Outstanding rose 0.59% year-over-year to $170.5 million; the TTM value through Sep 2025 reached $170.5 million, up 0.59%, while the annual FY2023 figure was $168.7 million, N/A changed from the prior year.
  • Shares Outstanding for Q2 2025 was $170.4 million at Biogen, up from $169.5 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $172.9 million in Q2 2021 and troughed at $23.8 million in Q3 2021.
  • A 5-year average of $157.5 million and a median of $169.4 million in 2024 define the central range for Shares Outstanding.
  • On a YoY basis, Shares Outstanding climbed as much as 626.47% in 2021 and fell as far as 8.74% in 2021.
  • Year by year, Shares Outstanding stood at $170.8 million in 2021, then fell by 1.23% to $168.7 million in 2023, then rose by 0.47% to $169.5 million in 2024, then rose by 0.59% to $170.5 million in 2025.
  • Business Quant data shows Shares Outstanding for BIIB at $170.5 million in Q3 2025, $170.4 million in Q2 2025, and $169.5 million in Q3 2024.